|By PR Newswire||
|September 4, 2014 06:00 AM EDT||
LINCOLNSHIRE, Ill., Sept. 4, 2014 /PRNewswire/ -- TOLMAR Pharmaceuticals, Inc., focused on specialty pharmaceutical products, is partnering with the not-for-profit organization ZERO – The End of Prostate Cancer in a series of events this fall that will bring together cancer survivors, healthcare providers, family, friends, athletes, and businesses united in their desire to fight prostate cancer.
TOLMAR Pharmaceuticals is participating in the 26+ run/walk events hosted by ZERO across the nation in the months of September, October, and November to raise funds and awareness of prostate cancer, the second leading cause of cancer death in American men after lung cancer. The disease affects one in seven men.
"TOLMAR Pharmaceuticals proudly supports the ZERO Prostate Cancer Challenge, the largest men's health event series in the nation," said Susan Rodriguez, CEO, TOLMAR Pharmaceuticals. "Along with our parent company, TOLMAR Inc., we have a long history of supporting patients with advanced prostate cancer, their healthcare providers, and their communities. As the distributor and marketer of ELIGARD® (leuprolide acetate for injectable suspension) we are honored to partner with ZERO to help raise awareness of prostate cancer."
TOLMAR Pharmaceuticals will also participate in the inaugural 2014 ZERO Regional Champions Leadership Conference, a Washington, DC, event pairing 50 leading prostate cancer advocates and medical professionals with elected officials to address patient access and care issues and make prostate cancer research a federal funding priority, in mid-September.
"We are grateful for the support from TOLMAR to help save lives and keep families together," said ZERO CEO Jamie Bearse. "With help from our partners, we're taking a huge step closer to creating Generation ZERO – the first generation of men free from prostate cancer."
In 2014, 233,000 new U.S. cases of prostate cancer will be diagnosed and 29,480 men will die of the disease, according to the National Cancer Institute (www.cancer.gov/cancertopics/types/prostate). The American Urological Association estimates 5-10 percent of newly diagnosed cases involve advanced disease, and some men who were initially treated with surgery or radiation therapy later develop a recurrence.
TOLMAR is a fully integrated pharmaceutical company focused on the development, approval, and commercialization of specialty pharmaceutical products. TOLMAR Pharmaceuticals is based in Lincolnshire, IL, with TOLMAR global headquarters, product development, and manufacturing facilities based in Fort Collins, CO. TOLMAR Pharmaceuticals has the exclusive distribution rights for ELIGARD® (leuprolide acetate for injectable suspension) in the U.S. and Puerto Rico. ELIGARD is a gonadotropin releasing hormone (GnRH) agonist prescribed for the treatment of advanced prostate cancer, developed and manufactured by TOLMAR Inc. "TOLMAR" refers to TOLMAR Holding Inc. and its wholly owned operating subsidiaries, TOLMAR Inc. (product development and manufacturing), TOLMAR Therapeutics, Inc. (licensing), and TOLMAR Pharmaceuticals, Inc. (sales and marketing). For more information about the company, please visit www.tolmar.com. Information about ELIGARD is available at http://www.eligard.com. For complete ELIGARD prescribing information, please go to: http://www.eligard.com/Docs/Pdf/TOLMAR%20Pharmaceuticals_Web_PI_05-07-14.pdf
© 2014 TOLMAR Pharmaceuticals, Inc. All rights reserved. TOLMAR and ELIGARD are trademarks of the TOLMAR group.
SOURCE TOLMAR Pharmaceuticals, Inc.
May. 4, 2016 12:45 AM EDT Reads: 1,174
May. 4, 2016 12:15 AM EDT Reads: 1,107
May. 3, 2016 11:45 PM EDT Reads: 999
May. 3, 2016 11:30 PM EDT Reads: 1,233
May. 3, 2016 11:00 PM EDT Reads: 1,277
May. 3, 2016 11:00 PM EDT Reads: 1,202
May. 3, 2016 10:45 PM EDT Reads: 759
May. 3, 2016 10:00 PM EDT Reads: 1,204
May. 3, 2016 10:00 PM EDT Reads: 1,313
May. 3, 2016 09:45 PM EDT Reads: 323
May. 3, 2016 08:45 PM EDT Reads: 1,278
May. 3, 2016 08:45 PM EDT Reads: 962
May. 3, 2016 08:30 PM EDT Reads: 1,198
May. 3, 2016 08:00 PM EDT Reads: 1,041